SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

31 Jul 2025 Evaluate
The sales slipped to Rs. 2927.53 millions, down -33.40% for the June 2025 quarter as against Rs. 4396.02 millions during the year-ago period.The company reported a drastic decline of -86.06% in the quarter ended June 2025 to Rs. 137.08  millions from Rs. 983.41 millions  .The company reported a degrowth in operating Profit to 421.49 millions from 1286.33 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 2927.53 4396.02 -33.40 2927.53 4396.02 -33.40 14768.37 15585.80 -5.24
Other Income 78.56 48.07 63.43 78.56 48.07 63.43 205.09 125.44 63.50
PBIDT 421.49 1286.33 -67.23 421.49 1286.33 -67.23 3428.08 4744.65 -27.75
Interest 45.83 26.70 71.65 45.83 26.70 71.65 82.96 139.97 -40.73
PBDT 375.66 1465.89 -74.37 375.66 1465.89 -74.37 4109.16 4604.68 -10.76
Depreciation 201.87 162.79 24.01 201.87 162.79 24.01 655.42 596.99 9.79
PBT 173.79 1303.10 -86.66 173.79 1303.10 -86.66 3453.74 4007.69 -13.82
TAX 36.71 319.69 -88.52 36.71 319.69 -88.52 859.48 1011.73 -15.05
Deferred Tax -6.96 13.89 -150.11 -6.96 13.89 -150.11 122.95 15.87 674.73
PAT 137.08 983.41 -86.06 137.08 983.41 -86.06 2594.26 2995.96 -13.41
Equity 129.01 129.01 0.00 129.01 129.01 0.00 129.01 129.01 0.00
PBIDTM(%) 14.40 29.26 -50.80 14.40 29.26 -50.80 23.21 30.44 -23.75

Neuland Laboratories Share Price

14948.20 -130.70 (-0.87%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×